API
< Back to all clusters
[BUSINESS] · South Korea, Germany · 5 sources

started · updated

South Korean biotech firms target global partnerships at BIO-Europe 2026

South Korean pharmaceutical and biotechnology companies, Alteogen and Jeil Pharmaceutical, are participating in the BIO-Europe 2026 conference in Cologne, Germany, to pursue technology exports and global partnerships.

Alteogen is promoting its multi-target macular degeneration drug candidate, ALTS-OP01, alongside its subcutaneous injection platform, Hybrozyme. The company aims to diversify its revenue streams by transitioning from a platform provider to a drug licensor. ALTS-OP01 is designed to inhibit four targets to treat retinal vascular diseases, targeting a market projected to reach $23 billion by 2031.

Jeil Pharmaceutical is seeking global collaborations for several key assets, including JP-2266, a dual SGLT1/SGLT2 inhibitor for type 2 diabetes, and JP9441, a SOS1 inhibitor targeting KRAS-mutated solid tumors. Additionally, the company is looking to expand the overseas licensing of its diabetes combination therapy, Duglow.

Entities

Alteogen · BIO-Europe 2026 · Cologne · Jeil Pharmaceutical · South Korea